Overactive Bladder Treatment Market Company Profiles, Market Segments, Landscape 2027
Market Research Future (MRFR) studied the global overactive
bladder treatment market 2021 in the review period .As per MRFR daat, the
overactive bladder treatment market is expected to thrive at 3.1% CAGR during
the forecast tenure, the global overactive bladder treatment market is expected
to earn decent value.
Market Drivers and Restraints
The rise in the number of patients with urinary urgency and
high frequency, and nocturia; typically diagnosed with overactive bladder (OAB)
can boost the need for effective treatment. The rise in occurrences of
neurological diseases, especially among the growing geriatric group, can prompt
the need for OAB management that can support the expansion of the global OAB market
in the assessment period. In addition, upgradation and innovations of
intravesical therapies and rapid commercialization of such new launches by
pharma companies can prompt the market rise in the assessment tenure.
On the other hand, issues with funding new solutions and
identification of undesired systemic effects can hinder the OAB market growth
in the evaluation period.
Segment Assessment
The segment assessment of the global overactive bladder
treatment market is based on non-pharmacological treatment, pharmacotherapy,
and disease.
The pharmacotherapy-based segments of the overactive bladder
treatment market are anticholinergics, neurostimulation, Botox, and mirabegron
among others. The anticholinergics segment studies solifenacin, fesoterodine,
oxybutynin, tolterodine, darifenacin, and trospium among others. The segment of
anticholinergic is expected to earn considerable profit due to the high
efficacy of treatment. In addition, the availability of numerous types of
anticholinergics that are compatible with all body types can favor the
market.
The non-pharmacological treatment-based segments of the
global overactive bladder treatment market are behavioral therapy, dietary and
fluid modifications, overactive
bladder medication and pelvic floor muscle rehabilitation among others. The
adoption of non-pharmacological treatments due to its non-invasive nature and
growing preference among patients can underpin the rise of the OAB market.
Behavioral therapy is gaining prominence among people, hence the behavioral
therapy segment is likely to thrive in the assessment period.
The disease-based segments of the OAB market are neurogenic overactive
bladder and idiopathic overactive bladder. The neurogenic overactive bladder
segment studies OAB in Parkinson's disease, the overactive bladder in stroke,
OAB in spinal cord injury, and the overactive bladder in several other
disorders. The growing cases of overactive bladder caused due to neurological
issues can cause the segment to rise in the assessment period. The increase in
number of patients that are reported for overactive bladder due to Parkinsonism
can add to the market upsurge. The hike in count of stroke cases can prompt the
market rise in the analysis period.
Regional Analysis
The market of overactive bladder treatment is assessed
across the Americas, Asia Pacific, Europe, and the Middle East and Africa. In
North America, the overactive bladder treatment is expected to thrive at a
considerable pace owing to expansion of geriatric populace and rise in
incidences of urinary and OAB incontinence symptoms. In addition, the
introduction of healthcare coverage systems, such as; Medicare can add to the
rise of the market in the Americas . According to the data by National
Association for Continence (NAFC), around 25 million Americans adults
experience chronic urinary incontinence and transients. The range is around 75
to 80% for women suffering from overactive bladder. In Europe, the market of
overactive bladder looks lucrative. The rise in occurrences of OAB and hike in
healthcare expenditure are causes that are likely to prompt the market in the
assessment period. In Asia Pacific, the availability of affordable
reimbursement options can aid the regional OAB market to surge. The increase in
cases of OAB among geriatric population, along with rise in cognizance of its
modern treatment can prompt APAC market in the review tenure. The existence of
robust medical setup and launch of initiatives taken by APAC governments to
support medical attention for the middle class population can favor the
regional OAB market. In the Middle East region and Africa, the overactive
bladder treatment market can witness sluggish growth owing to socio-political
backwardness.
Key Players
Astellas Pharma Inc., Pfizer, Inc., Allergan, Plc., Teva
Pharmaceutical Industries Ltd., Mylan N.V., Hisamitsu Pharmaceutical Co., Inc.,
Endo International Plc, Sanofi S. A., Aurobindo Pharma Limited, Intas
Pharmaceuticals Ltd., Johnson & Johnson, Apotex Inc., Medtronic PLC,
Macleods Pharmaceuticals Ltd., and Cogentix Medical, Inc., are some top-notch
companies that are operating in the overactive bladder treatment market as
listed by MRFR.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Comments
Post a Comment